NCT03099525

Brief Summary

The objectives of this single center, prospective, non-interventional cohort is to understand patient characteristics, general treatment patterns, effectiveness/safety of conventional disease modifying antirheumatic drug (DMARD) and biologic DMARD treatments in rheumatoid arthritis patients with ILD in the real-world setting

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 26, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 4, 2017

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

June 17, 2020

Status Verified

June 1, 2020

Enrollment Period

4.4 years

First QC Date

January 26, 2017

Last Update Submit

June 16, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mortality

    Comparison of prognosis such as mortality between RA-ILD and RA-non ILD

    5 years

Secondary Outcomes (5)

  • Pulmonary function test

    5 years

  • DAS28(Disease Activity Score in 28 joint)

    5 years

  • SDAI(Simple Disease Activity Index)

    5 years

  • CDAI(Clinic Disease Activity Index)

    5 years

  • Change of DAS28

    5 years

Study Arms (2)

RA-ILD

Patients who are diagnosed with ILD. No intervention in this study.

Other: ILD

RA-non ILD

Patients who are not diagnosed with ILD. No intervention in this study.

Other: ILD

Interventions

ILDOTHER

This is an observational study without any intervention.

RA-ILDRA-non ILD

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Korean patients diagnosed with RA with normal chest CT result within 2 years of clinical visit. Korean patients diagnosed with RA-ILD with chest CT results indicating ILD within 2 years of clinical visit.

You may qualify if:

  • Patients who satisfy the 1987 American college of rheumatology (ACR) or 2010 ACR/EULAR classification criteria for RA adult patients
  • Patients who are more than 19 years old
  • Patients who have checked chest CT scanning within 2 years
  • Patients who provide a written consent of participating in this study

You may not qualify if:

  • Patients who are aged under 19 years old
  • Patients who are pregnant
  • Patients who dose not provide a written consent of participating in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hanyang University

Seoul, 04763, South Korea

RECRUITING

Related Publications (1)

  • Kim H, Cho SK, Song YJ, Kang J, Jeong SA, Kim HW, Choi CB, Kim TH, Jun JB, Bae SC, Yoo DH, Lee H, Park DW, Sohn JW, Yoon HJ, Hong SJ, Yoo SJ, Choi YW, Lee Y, Kim SH, Sung YK. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single-center prospective cohort. Arthritis Res Ther. 2023 Mar 17;25(1):43. doi: 10.1186/s13075-023-03024-8.

MeSH Terms

Conditions

Arthritis, RheumatoidLung Diseases, Interstitial

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesLung DiseasesRespiratory Tract Diseases

Study Officials

  • Yoon-Kyoung Sung, MD,PhD,MPH

    Hanyang University Hospital for Rheumatic Diseases

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yoon-Kyoung Sung, MD,PhD,MPH

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

January 26, 2017

First Posted

April 4, 2017

Study Start

October 1, 2016

Primary Completion

March 1, 2021

Study Completion

March 1, 2022

Last Updated

June 17, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations